Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Johnson & Johnson
Woman and Man Max 99 years
Johnson & Johnson Consumer & Personal Products Worldwide, Division of Johnson & Johnson Consumer Companies, Inc
Update Il y a 4 ans
A four week study to evaluate how well a Medical Device mouth rinse treats gingivitis compared to a medicine mouth rinse
To determine the efficacy of Listerine®Advanced Defence Gum Treatment (a mouthwash classified as Class IIa medical device already on the market in the EU) on whole-mouth mean gingival bleeding index (...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Ethicon Inc., a Johnson & Johnson Co
Update Il y a 4 ans
A study of the superior effect of EVARREST™ Fibrin Sealant Patch as compared to Standard Treatment in controlling bleeding during liver surgery
To evaluate the safety and hemostatic effectiveness of EVARREST Fibrin Sealant Patch versus standard of care treatment (SoC) in controlling parenchymal bleeding during hepatic surgery.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Johnson & Johnson Pharmaceutical Research & Development, L.L.C
Update Il y a 4 ans
A Phase 3, Randomized, Double-Blind Study Of Ceftobiprole Medocaril Versus Vancomycin With Ceftazidime in The Treatment Of Complicated Skin And Skin Structure Infections
To demonstrate the noninferiority of ceftobiprole/placebo compared with Vancomycin/ceftazidime with respect to clinical cure rate in subjects with complicated skin and skin structure infections (cSSS...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
McNeil AB (Johnson & Johnson Consumer and Personal Products Worldwide, J&J CPPW)
Update Il y a 4 ans
Efficacy and safety following use of a novel nicotine replacement therapy. A multicenter, randomized, double blind, placebo-controlled, parallel group, 52-week study in smokers motivated to quit
To evaluate the efficacy of NMS versus placebo in smokers to achieve continuous abstinence from smoking from the week 2 visit until and including the week 6, week 24, and week 52 visits, respectively.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Johnson & Johnson Pharamceutical Research & Development, L.L.C
Update Il y a 4 ans
Randomized, Double-Blind, Active-Control, Parallel Group, 90-Day Safety Study of CG5503 Immediate Release or Oxycodone Immediate Release in Subjects With Chronic Pain from Low Back Pain or Osteoarthritis of the Hip or Knee
The primary objective of the study is to evaluate the safety profile of CG5503 base IR 50 mg or 100 mg taken every 4 to 6 hours as needed over the long term exposure of 90 days
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Johnson & Johnson Pharamceutical Research & Development, L.L.C
Update Il y a 4 ans
A Randomized, Double-Blind, Active- And Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate The Efficacy And Safety of Multiple Doses of CG5503 Immediate Release Formulation In Subjects Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease
The primary objective of this study is to determine the efficacy of CG5503 immediate-release (IR) using the sum of pain intensity difference (SPID) over 5 days compared with placebo, and to assess the...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Johnson & Johnson Taiwan Ltd
Update Il y a 4 ans
The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate whether familial relationships and psychological status of participants or caregivers as well as Attention Deficit Hyperactivity Disorder (ADHD) symptoms of pa...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Johnson & Johnson Pharmaceutical Research & Development
Update Il y a 4 ans
A randomized, open-label, multicenter study evaluating thrombovascular events in subjects with cancer receiving chemotherapy and administered epoetin alfa once or three times a week for the treatment of anemia
The primary objective is to compare the safety with respect to the incidence of clinically relevant and objectively confirmed TVEs in 2 dosing regimens of epoetin alfa when used following guidelines f...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Johnson & Johnson
Update Il y a 4 ans
Johnson & Johnson CR014764 : Essai de phase 3 randomisé évaluant l’efficacité et la tolérance d’un traitement par trabectédine chez des patients ayant un cancer du sein. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de l’essai est d’évaluer l’efficacité et la tolérance d’un traitement par trabectédine chez des patients ayant un cancer du sein. Les patients sont répartis, en fonction du profil de leur ...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Johnson & Johnson Pharmaceutical Research & Development, L.L.C
Update Il y a 4 ans
A Study to Evaluate the Pharmacokinetics and Safety of Doripenem in Children and Adolescents with Cystic Fibrosis
To assess the pharmacokinetics of doripenem after a single 30 mg/kg doripenem 4-hour i.v. infusion administered to pediatric subjects 6 to 17 years of age, inclusive, with cystic fibrosis (CF). Safety...
Country
None
organs
None
Specialty
None
More information
Previous
1
2
3
4
Next